PTC Industries shares up 1.8% on strong military partnership outlook
PTC Industries shares rose 1.8% in early trade after management highlighted the strategic importance of its latest Memorandum of Understanding (MoU) with French aerospace major Safran. Unlike their earlier MoU focused on civil aviation, the new agreement targets military operations—marking a major shift in scope.
Chairman & MD Sachin Agarwal told CNBC-TV18 that the company expects significant growth from this MoU, which aligns with other ongoing defense-related investments. He added that PTC Industries anticipates operating margins in the mid-to-high 20% range for FY26.
Agarwal also revealed that the company plans to sign several similar agreements over the next six months, indicating a strong pipeline of defense sector collaborations.
PTC Industries shares opened at ₹15,080.00 and hit a high of ₹15,488.00 during the day, while the low stood at ₹15,013.00. The stock is trading well above its 52-week low of ₹9,756.30 but remains below the 52-week high of ₹17,995.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
13 minutes ago
- Business Upturn
V2 Retail Q1 FY26 business update: Company reports 51% YoY revenue growth, adds 28 new stores
V2 Retail Limited has reported a strong start to FY26, delivering impressive growth in its Q1 business update. The company's standalone revenue surged to ₹628 crore in Q1 FY26, marking a 51% year-on-year jump from ₹415 crore in Q1 FY25. This performance highlights the success of its product-first approach, robust sell-through rates, and deeper market reach. Same-store sales growth (SSSG) normalized at 10%, despite an early Eid impact in April. May and June recorded strong double-digit growth, reflecting steady consumer demand and smart assortment planning. Sales per square foot for Q1 stood at ₹957, showing solid store-level productivity—even with a higher contribution from new stores. This was made possible through improved merchandising, faster stock replenishments, and strict inventory control. V2 Retail also expanded its footprint by opening 28 new stores during the quarter while closing one underperforming outlet. The total store count now stands at 216, covering a retail area of 23.48 lakh sq. ft. The company continues to focus on Tier 2 and Tier 3 cities, strengthening its mission to bring affordable fashion to emerging India. The company emphasized its strong momentum going into FY26, driven by innovation, data-backed merchandising, and customer trust. With an expanding footprint and a clear focus on value fashion, V2 Retail is well-positioned to lead in India's fast-evolving retail landscape. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
13 minutes ago
- Business Upturn
Aurobindo Pharma's subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys'
Aurobindo Pharma's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzumab biosimilar. This approval follows the positive opinion issued by the European Medicines Agency's (EMA) CHMP in April 2025, recommending the product for authorization. Dazublys™ is a biosimilar of trastuzumab, a widely used monoclonal antibody in the treatment of HER2-positive breast and gastric cancers. With this latest approval, Dazublys™ becomes CuraTeQ's third EMA-approved biosimilar, following Dyrupeg™ (approved in April 2025) and Zefylti™ (approved in February 2025). It also marks the fourth biosimilar approval for CuraTeQ in the European region, including Bevqolva™, which received a green light from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in December 2024. This continued string of regulatory successes further strengthens Aurobindo Pharma's global biosimilar portfolio and underscores the company's commitment to expanding access to high-quality, affordable biologics in key regulated markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
CNBC
30 minutes ago
- CNBC
A bare-bones deal is Europe's best hope in trade talks with the U.S., sources say
The clock is ticking in trade talks between Washington and the European Union, with European officials now saying their best hope is striking a "political" deal before a key July 9 deadline, three sources told CNBC. Concrete details of such a trade arrangement would have to be worked out at a later time. "The U.S. proposal from last week is aimed at an agreement in principle," one EU official, who did not want to be named due to the sensitivity of the talks, told CNBC, adding that this agreement in principle would then "be negotiated out into a proper trade agreement at a later stage." Previously close allies, the U.S. and EU have had a fractious relationship amid disagreements over trade and support for embattled Ukraine in the months since the start of U.S. President Donald Trump's second term. Tensions escalated in early April, when White House announced a spate of reciprocal tariffs against most global trade partners, including a 20% levy on the EU. All such duties have been temporarily reduced until July 9 to facilitate talks. The U.S. sent a new proposal to the EU's negotiating team last week. European negotiators are having face-to-face talks with their American counterparts later this week with the view to get a deal done in the coming days. Total bilateral trade in goods between the EU and the U.S. accounted for 851 billion euros ($1 trillion) in 2023, according to figures from the European Commission. European officials expect a new update on the negotiations Friday, but the situation is fluid. On Monday, European ambassadors had conversations about the state of play in the trade negotiations. Lithuania's Minister of Finance Rimantas Šadžius told CNBC on Wednesday that he is "slightly optimistic" there will be a trade compromise between both sided of the Atlantic. Despite this, sources told CNBC that, despite efforts to reach a trade compromise, the EU is preparing for any possible outcomes, including the return of reciprocal tariffs. "The general sense is that in the coming days and weeks, all outcomes, ranging from a successful deal on a framework agreement all the way to higher US tariffs with additional sectors, are still possible," the same EU official told CNBC. This sentiment was also shared by European Commission President Ursula von der Leyen last Friday. "We are ready for a deal. At the same time, we are preparing for the possibility that no satisfactory agreement is reached," she said at a press conference. The European Commission was not immediately available for comment when contacted by CNBC Wednesday about an update to the talks. Another EU official, also speaking to CNBC on the condition of anonymity, said there is an awareness in Brussels that it is almost impossible to return to the trade relationship that the EU and U.S. enjoyed before the April 2 announcement of reciprocal tariffs. A third EU official, who also chose to speak anonymously, told CNBC that there is a risk that the outcome of the talks will be an "asymmetrical" deal, under which the EU will not escape some additional U.S. levies. Nonetheless, the bloc is looking to get concessions in critical areas for its economy, including automotive, semiconductors and pharmaceuticals, all three sources confirmed. The first EU official added that some member states will only agree to a deal in principle if there is a commitment from the Trump administration to "upfront tariff relief." The European Commission, the executive arm of the EU, negotiates trade with other parts of the world, but its proposals and position reflects the thinking of the 27 capitals.
